Arcoma

Arcoma Capital Intensity

The Capital Intensity Ratio of Arcoma (ARCOMA.ST) as of Oct 23, 2026 is 73.89 %. In the previous year, Capital Intensity Ratio was 51.31 % — a change of 44.00% (higher).

Capital Intensity

73.89 %

YoY

44.00%

Last updated:

Capital Intensity Ratio of Arcoma is 2025 73.89 % . Capital Intensity Ratio of Arcoma was 2024 51.31 % . It decreases by 44.00% higher compared to the previous year.

The Arcoma Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
63.84 SEK
Jan 1, 2019
62.34 SEK
Jan 1, 2020
80.93 SEK
Jan 1, 2021
67.68 SEK
Jan 1, 2022
80.24 SEK
Jan 1, 2023
50.28 SEK
Jan 1, 2024
51.31 SEK
Jan 1, 2025
73.89 SEK
The Arcoma Capital Intensity history
YEARCapital IntensityYoY
73.89 %+44.00%
51.31 %+2.06%
50.28 %-37.34%
80.24 %+18.56%
67.68 %-16.38%
80.93 %+29.83%
62.34 %-2.36%
63.84 %-13.91%
74.16 %+6.24%
69.80 %+2.14%
68.34 %+12.53%
60.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcoma Stock analysis

What does Arcoma do? Arcoma AB generates revenue through the sale of its digital radiographic systems, which include complete systems like ceiling suspensions and floor-mounted units, as well as detectors and components such as overhead tube cranes and radiographic tables. The company markets its products under the IMIX brand, through private label distributors, and as original equipment manufacturer (OEM) solutions. Its primary customers are hospitals, clinics, imaging centers, and private practices seeking digital imaging technology with advanced mobile positioning systems. The Precision and Elite mobile imaging table series are key product offerings within its portfolio. The company's business model relies on direct sales of IMIX-branded systems to healthcare facilities, while also supplying components to private label distributors and OEM partners. These channels allow Arcoma to reach a broad range of healthcare providers across different segments. The firm's product range targets facilities requiring flexible, mobile imaging solutions for diagnostic procedures. Arcoma AB's revenue streams are derived from the sale of complete radiographic systems, system components, and mobile imaging tables, all designed for healthcare environments. The IMIX brand represents the company's direct-to-customer offering, while private label and OEM arrangements provide additional distribution pathways. The Precision and Elite series specifically cater to the needs of medical practices requiring mobile diagnostic equipment. Arcoma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcoma stock

Capital Intensity Ratio of Arcoma is 73.89 % in 2025.

Capital Intensity Ratio of Arcoma changed from 51.31 % to 73.89 %, representing a 44.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Arcoma since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Arcoma with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Arcoma

All Key Metrics — Arcoma